Luz Ángela Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Luz Ángela Castro has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- María Inés Álvarez
University of Valle
5 shared publications Ernesto Martinezbuitrago
University of Valle
1 shared publicationErnesto Martínez
Department of Internal Medicine, Universidad del Valle, University Hospital of Valle, Cali, Colombia
1 shared publication- Ernesto Martínez-Buitrago
SIES SALUD
1 shared publication - Gustavo Giusiano
Departamento Micología, Instituto de Medicina Regional, Universidad Nacional de Nordeste, CONICET, Resistencia 3500, Argentina
1 shared publication Luz Ángela González
Universidad del Valle
1 shared publication
Latest Publications
- 1 September 2021
- Published by Elsevier in Journal of Medical Mycology
- Vol. 31 (3) , 101172
Nail dermatophytoma in HIV-infected patients in Cali, Colombia
- 1 September 2021
- Published by Elsevier in Journal of Medical Mycology
- Vol. 31 (3) , 101172
Nail dermatophytoma in HIV-infected patients in Cali, Colombia
- Open Access
- 30 December 2019
- Published by Universidad del Valle in Colombia Medica
- Vol. 50 (4) , 293-98
Candida auris infection in the central catheter of a patient without sepsis symptoms
Background: Candida auris is an emerging yeast frequently reported as resistant to multiple antifungal drugs commonly used to treat Candida infections. This specie can colonize the patient’s skin and has great ability for producing outbreaks in hospitals. C. auris is phylogenetically related to other Candida species, can be misidentified using conventional biochemical or commercial methods and requires specific technology for its identification. Case report: We report the first isolate of C. auris in Cali, Colombia, from a central venous catheter in a 37-year-old patient with rheumatoid arthritis and endocarditis who did not have symptoms of sepsis. The yeast was initially misidentified as C. haemulonii using the Phoenix® system and subsequently identified as C. auris by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry. The broth microdilution method was used to determine the minimum inhibitory concentration; the isolate was susceptible to fluconazole, itraconazole, voriconazole and amphotericin B. Conclusions: This report contributes to knowledge of the epidemiology of C. auris infections in individuals with underlying disease and describes an isolate with a behavior different from what is usually reported.
- 30 December 2019
- Published by Universidad del Valle in Colombia Medica
- Vol. 50 (4) , 293-98
Open AccessCandida auris infection in the central catheter of a patient without sepsis symptoms
Background: Candida auris is an emerging yeast frequently reported as resistant to multiple antifungal drugs commonly used to treat Candida infections. This specie can colonize the patient’s skin and has great ability for producing outbreaks in hospitals. C. auris is phylogenetically related to other Candida species, can be misidentified using conventional biochemical or commercial methods and requires specific technology for its identification. Case report: We report the first isolate of C. auris in Cali, Colombia, from a central venous catheter in a 37-year-old patient with rheumatoid arthritis and endocarditis who did not have symptoms of sepsis. The yeast was initially misidentified as C. haemulonii using the Phoenix® system and subsequently identified as C. auris by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry. The broth microdilution method was used to determine the minimum inhibitory concentration; the isolate was susceptible to fluconazole, itraconazole, voriconazole and amphotericin B. Conclusions: This report contributes to knowledge of the epidemiology of C. auris infections in individuals with underlying disease and describes an isolate with a behavior different from what is usually reported.
- Open Access
- 30 December 2015
- Vol. 46 (4) , 202-203
Laryngeal histoplasmosis: report of the first case in Colombia
- 30 December 2015
- Vol. 46 (4) , 202-203
Open AccessLaryngeal histoplasmosis: report of the first case in Colombia
- Open Access
- 1 December 2015
- Published by Universidad del Valle in Colombia Medica
- Vol. 46 (4) , 202-203
Laryngeal histoplasmosis: report of the first case in Colombia
Dear Editor, With regard to the article "Laryngeal histoplasmosis: report of the first case in Colombia" published by Moriones et al. Colomb Med (Cali). 2014; 45(4):186-9 1 , we would like to provide the following comments: Histoplasmosis is a common systemic mycosis in Colombia, and because no reporting requirements exist, a national survey was designed to understand aspects of the disease that could be collected from diagnosed cases to provide useful information. A total of 434 patient surveys from 20 departments were analyzed through 2008; the majority of the reports were from Antioquia, followed by del Valle and Cundinamarca. Thus, the results from these surveys did not indicate that histoplasmosis is more commonly diagnosed in these departments, as the authors had expressed, but rather that these were the most informative departments 2, as this was a voluntary report.
- 1 December 2015
- Published by Universidad del Valle in Colombia Medica
- Vol. 46 (4) , 202-203
Open AccessLaryngeal histoplasmosis: report of the first case in Colombia
Dear Editor, With regard to the article "Laryngeal histoplasmosis: report of the first case in Colombia" published by Moriones et al. Colomb Med (Cali). 2014; 45(4):186-9 1 , we would like to provide the following comments: Histoplasmosis is a common systemic mycosis in Colombia, and because no reporting requirements exist, a national survey was designed to understand aspects of the disease that could be collected from diagnosed cases to provide useful information. A total of 434 patient surveys from 20 departments were analyzed through 2008; the majority of the reports were from Antioquia, followed by del Valle and Cundinamarca. Thus, the results from these surveys did not indicate that histoplasmosis is more commonly diagnosed in these departments, as the authors had expressed, but rather that these were the most informative departments 2, as this was a voluntary report.
- Open Access
- 1 January 2015
- Published by Universidad de Antioquia in IATREIA
- Vol. 28 (4) , 368-377
Candida en la cavidad oral de pacientes con VIH en Cali, Colombia: determinación de especies y sensibilidad al fluconazol
Candida en la cavidad oral de pacientes con VIH en Cali, Colombia: determinación de especies y sensibilidad al fluconazol
- 1 January 2015
- Published by Universidad de Antioquia in IATREIA
- Vol. 28 (4) , 368-377
Open AccessCandida en la cavidad oral de pacientes con VIH en Cali, Colombia: determinación de especies y sensibilidad al fluconazol
Candida en la cavidad oral de pacientes con VIH en Cali, Colombia: determinación de especies y sensibilidad al fluconazol
- 21 October 2012
- Published by Springer Nature in Mycopathologia
- Vol. 175 (1-2) , 91-98
Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia
Candida albicans is the most frequently isolated yeast from the oral cavity of HIV/AIDS individuals. The use of fluconazole has increased the number of resistant or less-sensitive Candida species different than C. albicans. The purpose of this study was to identify the Candida species producing pseudomembranous candidiasis in patients suffering from AIDS, their relationship with CD4+ counts and their sensitivity to fluconazole and itraconazole. We studied 71 patients at a hospital in the city of Cali. Samples of white plaque were seeded on CHROMagar Candida, yeast identification was done with API 20C Aux, and susceptibility testing was determined by E test. Ninety-three yeast isolates were obtained, 52 single and 41 mixed. C. albicans was the most isolated, followed by C. glabrata. An increased frequency of isolates and variety of Candida species occurred in patients with a CD4+ cell count ≤100 cells/mm3 without significant differences (p = 0.29). The susceptibility study showed that 8 (8.6 %) isolates were resistant to fluconazole and 11 (11.8 %) to itraconazole, while 6 (8.8 %) C. albicans were simultaneously resistant. No association was found between the isolates of C. albicans or Candida species different than C. albicans and the use of fluconazole (p = 0.21). The results of this study indicate that in the tested population, fluconazole continues to be the best treatment option for oropharyngeal candidiasis in patients suffering from AIDS (HIV/AIDS); however, susceptibility tests are necessary in patients who present therapeutic failure.
- 21 October 2012
- Published by Springer Nature in Mycopathologia
- Vol. 175 (1-2) , 91-98
Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia
Candida albicans is the most frequently isolated yeast from the oral cavity of HIV/AIDS individuals. The use of fluconazole has increased the number of resistant or less-sensitive Candida species different than C. albicans. The purpose of this study was to identify the Candida species producing pseudomembranous candidiasis in patients suffering from AIDS, their relationship with CD4+ counts and their sensitivity to fluconazole and itraconazole. We studied 71 patients at a hospital in the city of Cali. Samples of white plaque were seeded on CHROMagar Candida, yeast identification was done with API 20C Aux, and susceptibility testing was determined by E test. Ninety-three yeast isolates were obtained, 52 single and 41 mixed. C. albicans was the most isolated, followed by C. glabrata. An increased frequency of isolates and variety of Candida species occurred in patients with a CD4+ cell count ≤100 cells/mm3 without significant differences (p = 0.29). The susceptibility study showed that 8 (8.6 %) isolates were resistant to fluconazole and 11 (11.8 %) to itraconazole, while 6 (8.8 %) C. albicans were simultaneously resistant. No association was found between the isolates of C. albicans or Candida species different than C. albicans and the use of fluconazole (p = 0.21). The results of this study indicate that in the tested population, fluconazole continues to be the best treatment option for oropharyngeal candidiasis in patients suffering from AIDS (HIV/AIDS); however, susceptibility tests are necessary in patients who present therapeutic failure.
- 1 September 2004
- Published by Springer Nature in Mycopathologia
- Vol. 158 (2) , 181-186
Onychomycosis in Cali, Colombia
This study presents the epidemiological and mycological aspects of 299 patients with nail lesions who were referred to three diagnostic laboratories in the city of Cali. The diagnosis of mycoses was...
- 1 September 2004
- Published by Springer Nature in Mycopathologia
- Vol. 158 (2) , 181-186
Onychomycosis in Cali, Colombia
This study presents the epidemiological and mycological aspects of 299 patients with nail lesions who were referred to three diagnostic laboratories in the city of Cali. The diagnosis of mycoses was...